EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy

Tianran Chen, Ying Wang, Xiaotong Chen, Yuxiang Li, Jingyi Guo, Fangcen Liu, Jie Shao, Jiayao Yan, Mengzhu Li, Jiaqi Nie, Qi Sun, Qin Liu und 1 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-013246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Tianran Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Comprehensive Cancer Centre, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Na…. Hauptthemen laut MEDLINE: CD28 Antigens, Antibodies, Bispecific, T-Lymphocytes, Immunotherapy. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangsu Province Key Research and Develpoment Program, The National Natural Science Foundation of China, Jiangsu Provincial Medical Key Discipline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bispecific T cell engagers have demonstrated promising clinical progress in both hematologic malignancies and solid tumors; however, their therapeutic efficacy is still limited by multiple challenges including T cell anergy resulting from single-signal activation exclusively through CD3 engagement. As a critical co-stimulatory molecule, CD28 enhances T-cell functionality through synergistic interaction with the TCR-mediated primary activation signal, thus potentiating antitumor efficacy. Non-superagonistic CD28 bispecific antibodies, while enhancing antitumor efficacy, can minimize systemic toxicity. Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1), a cancer-testis antigen overexpressed in diverse malignancies, emerges as a promising target for tumor-specific immunotherapy. Herein, the development of a dual-signal T-cell engager strategy targeting KK-LC-1, using a non-superagonist CD28-based co-stimulatory mechanism, is of critical importance.

Methods

Based on the successful acquisition of the designed ankyrin repeat proteins targeting KK-LC-1 and CD28 through phage display technology (KD=8.985 nM and 7.43 nM), we designed two T cell engagers (KK-LC-1×CD3 and KK-LC-1×CD28). The tumor-specific binding activity of KK-LC-1 designed ankyrin repeat protein was verified by surface plasmon resonance, flow cytometry, confocal microscopy, and in vivo imaging. We then fused it with CD3 single-chain variable fragment and CD28-designed ankyrin repeat protein, respectively, to construct two T cell engagers. Their biological activities and antitumor efficacy were systematically evaluated both in vitro and in vivo (n=5) using flow cytometric analysis, confocal microscopy imaging, and bioluminescence quantification.

Results

T-cell engagers KK-LC-1×CD3 and KK-LC-1×CD28 were successfully engineered and demonstrated high binding affinity for both KK-LC-1-positive tumor cells and T cells. Co-administration of these engagers significantly augmented T-cell activation and antitumor efficacy (88% vs 66%, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD28 AntigensAntibodies, BispecificT-LymphocytesImmunotherapyHumansAnimalsMiceLymphocyte Activation

Stichwörter der Autor:innen

Bispecific T cell engager - BiTECombination therapySolid tumor

Substanzen

CD28 AntigensAntibodies, Bispecific

Autor:innen und Institutionen

  • The Comprehensive Cancer Centre, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Clinical Cancer Institute of Nanjing University, Nanjing, China.
  • Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China baoruiliu@nju.edu.cn liuqin@nju.edu.cn sunqi@njglyy.com.
  • The Comprehensive Cancer Centre, Nanjing Drum Tower Hospital & Group's Suqian Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China baoruiliu@nju.edu.cn liuqin@nju.edu.cn sunqi@njglyy.com.

Förderung

  • Jiangsu Province Key Research and Develpoment Program
  • The National Natural Science Foundation of China
  • Jiangsu Provincial Medical Key Discipline
  • Nangjing Jiangbei New Area key research and development program
  • Nanjing Medical Key Laboratory of Oncology

Zitieren

APA

Chen, T., Wang, Y., Chen, X., Li, Y., Guo, J., Liu, F., Shao, J., Yan, J., Li, M., Nie, J., Sun, Q., Liu, Q., & Liu, B. (2026). Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013246

Vancouver

Chen T, Wang Y, Chen X, Li Y, Guo J, Liu F, et al. Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013246

BibTeX
@article{Chen2026,
  author = {Chen, Tianran and Wang, Ying and Chen, Xiaotong and Li, Yuxiang and Guo, Jingyi and Liu, Fangcen and Shao, Jie and Yan, Jiayao and Li, Mengzhu and Nie, Jiaqi and Sun, Qi and Liu, Qin and Liu, Baorui},
  title = {Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-013246}
}
Kostenlos starten →